NNovo Nordisk Read More Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold?2026-08-19 Quick Read LLY dominates the GLP-1 race with 48% revenue growth and an unpriced Retratrutide catalyst, while NVO…